Lite Strategy (LITS) Capital Expenditures (2010 - 2026)

Lite Strategy (LITS) posted quarterly Capital Expenditures of -$27000.0 for Q1 2026, down 485.71% quarter-over-quarter from $7000.0 in Q3 2023.

Lite Strategy (LITS) Capital Expenditures (2010 - 2026) Analysis & Trends

Lite Strategy's Capital Expenditures history runs 13 years deep, the most recent figure standing at -$27000.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to -$27000.0; the TTM figure through Mar 2026 stood at -$27000.0 (changed N/A YoY), while the FY2024 annual figure was $7000.0, down 80.0% from the prior year.
Capital Expenditures for Q1 2026 stood at -$27000.0, down from $7000.0 in the prior quarter.
The five-year high for Capital Expenditures was $306000.0 in Q2 2022, with the low at -$27000.0 in Q1 2026.
The 3-year median for Capital Expenditures is $35000.0 (2023), against an average of $87000.0.
The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 3725.0% in 2022, then slumped 88.56% in 2023.
Lite Strategy's Capital Expenditures stood at $306000.0 in 2022, then slumped by 97.71% to $7000.0 in 2023, then sank by 485.71% to -$27000.0 in 2026.
Business Quant data shows LITS's Capital Expenditures at -$27000.0 in Q1 2026, $7000.0 in Q3 2023, and $35000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Lite Strategy	35.71 Mn	28.17 Mn	-	-

Download Data